240 related articles for article (PubMed ID: 19276348)
1. Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
Plotnikov A; Varghese B; Tran TH; Liu C; Rui H; Fuchs SY
Cancer Res; 2009 Apr; 69(7):3165-72. PubMed ID: 19276348
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of prolactin receptor in breast cancer cells.
Li Y; Clevenger CV; Minkovsky N; Kumar KG; Raghunath PN; Tomaszewski JE; Spiegelman VS; Fuchs SY
Oncogene; 2006 Mar; 25(13):1896-902. PubMed ID: 16278670
[TBL] [Abstract][Full Text] [Related]
3. Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor.
Plotnikov A; Li Y; Tran TH; Tang W; Palazzo JP; Rui H; Fuchs SY
Cancer Res; 2008 Mar; 68(5):1354-61. PubMed ID: 18316598
[TBL] [Abstract][Full Text] [Related]
4. The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.
Fiorillo AA; Medler TR; Feeney YB; Wetz SM; Tommerdahl KL; Clevenger CV
Am J Pathol; 2013 Jan; 182(1):217-33. PubMed ID: 23159947
[TBL] [Abstract][Full Text] [Related]
5. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
6. Prolactin induces up-regulation of its cognate receptor in breast cancer cells via transcriptional activation of its generic promoter by cross-talk between ERα and STAT5.
Kavarthapu R; Tsai Morris CH; Dufau ML
Oncotarget; 2014 Oct; 5(19):9079-91. PubMed ID: 25193864
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
8. The prolactin receptor mediates HOXA1-stimulated oncogenicity in mammary carcinoma cells.
Hou L; Xu B; Mohankumar KM; Goffin V; Perry JK; Lobie PE; Liu DX
Int J Oncol; 2012 Dec; 41(6):2285-95. PubMed ID: 23064471
[TBL] [Abstract][Full Text] [Related]
9. Prolactin Receptor Expression is an Independent Favorable Prognostic Marker in Human Breast Cancer.
Hachim IY; Hachim MY; Lopez VM; Lebrun JJ; Ali S
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):238-45. PubMed ID: 26317306
[TBL] [Abstract][Full Text] [Related]
10. Negative regulation of prolactin receptor stability and signaling mediated by SCF(beta-TrCP) E3 ubiquitin ligase.
Li Y; Kumar KG; Tang W; Spiegelman VS; Fuchs SY
Mol Cell Biol; 2004 May; 24(9):4038-48. PubMed ID: 15082796
[TBL] [Abstract][Full Text] [Related]
11. Prolactin receptor gene transcriptional control, regulatory modalities relevant to breast cancer resistance and invasiveness.
Kavarthapu R; Dufau ML
Front Endocrinol (Lausanne); 2022; 13():949396. PubMed ID: 36187116
[TBL] [Abstract][Full Text] [Related]
12. Essential role of endogenous prolactin and CDK7 in estrogen-induced upregulation of the prolactin receptor in breast cancer cells.
Kavarthapu R; Dufau ML
Oncotarget; 2017 Apr; 8(16):27353-27363. PubMed ID: 28423697
[TBL] [Abstract][Full Text] [Related]
13. CAML promotes prolactin-dependent proliferation of breast cancer cells by facilitating prolactin receptor signaling pathways.
Lim JH; Kim TY; Kim WH; Park JW
Breast Cancer Res Treat; 2011 Nov; 130(1):19-27. PubMed ID: 21128111
[TBL] [Abstract][Full Text] [Related]
14. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
15. New mechanisms for PRLr action in breast cancer.
Clevenger CV; Gadd SL; Zheng J
Trends Endocrinol Metab; 2009 Jul; 20(5):223-9. PubMed ID: 19535262
[TBL] [Abstract][Full Text] [Related]
16. Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.
Sakamoto K; Triplett AA; Schuler LA; Wagner KU
Oncogene; 2010 Sep; 29(39):5359-69. PubMed ID: 20639901
[TBL] [Abstract][Full Text] [Related]
17. The Human Intermediate Prolactin Receptor I-tail Contributes Breast Oncogenesis by Targeting Ras/MAPK Pathway.
Shen S; Radhakrishnan SK; Harrell JC; Puchalapalli M; Koblinski J; Clevenger C
Endocrinology; 2024 Apr; 165(6):. PubMed ID: 38713636
[TBL] [Abstract][Full Text] [Related]
18. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.
Sutherland A; Forsyth A; Cong Y; Grant L; Juan TH; Lee JK; Klimowicz A; Petrillo SK; Hu J; Chan A; Boutillon F; Goffin V; Egan C; Tang PA; Cai L; Morris D; Magliocco A; Shemanko CS
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26586670
[TBL] [Abstract][Full Text] [Related]
19. Regulation of prolactin receptor levels and activity in breast cancer.
Swaminathan G; Varghese B; Fuchs SY
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):81-91. PubMed ID: 18204982
[TBL] [Abstract][Full Text] [Related]
20. Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge.
Goffin V
Pharmacol Ther; 2017 Nov; 179():111-126. PubMed ID: 28549597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
